What’s happening in the labs of pharma companies worldwide.
Some companies are repurposing or developing treatment, others are focusing on vaccines, tests or technology to deliver drugs in the body.

Existing drugs being repurposed

  • Gilead Sciences Inc’s (NASDAQ:GILD) antiviral medication remdesivir is undergoing the final phase of clinical trials, with results expected by the beginning of May.
  • AstraZeneca PLC (LON:AZN) is assessing the efficacy of Calquence, normally used for blood cancer.
  • Sanofi is focusing on Plaquenil/Hydroxychloroquine, used for malaria, and rheumatoid arthritis treatment Kevzara in conjunction with Regeneron.
  • Another repurposed arthritis treatment is Swiss giant Roche’s Actemra, with clinical results expected between June and July.
  • Ergomed PLC (LON:ERGO) is running trials for two antibodies, namilumab (IZN-101) and siltuximab. Interim data on the latter showed that 33% of patients saw clinical improvement, with a reduced need for oxygen support, while 43% stabilised.
  • Respiratory drug developer Synairgen PLC (LON:SNG) is testing its candidate SNG001, a formulation based on a interferon beta, a naturally occurring protein which orchestrates the body's antiviral responses.
  • CytoDyn Inc begun the first human trials for leronlimab (PRO 140), initially designed to treat HIV, in mid-April.

New treatment

  • GlaxoSmithKline PLC (LON:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) are cooperating to research coronaviruses using Vir’s antibody platform technology.
  • Tiziana Life Sciences PLC (LON:TILS) has developed a handheld inhaler that will allow the rapid delivery of TZLS-501, its drug to treat inflammation of the lung caused by the coronavirus.
  • The NHS is preparing to test the blood of coronavirus survivors to see if it can be used to treat patients.
  • Other groups are working on antibodies from people who have recovered, such as Takeda, Mount Sinai and Hopkins. The results can be used by vaccine developers as they will help understanding how the immune system works, said Tim Xu, investment associate at venture capital company Arix Bioscience PLC (LON:ARIX).

Vaccines

  • GlaxoSmithKline PLC (LON:GSK) and French rival Sanofi have agreed to develop a candidate that is scheduled to enter clinical trials in the second half of 2020 and be ready by 2021.
  • Biotech company Moderna Inc (NASDAQ:MRNA) developed a candidate in only 63 days, entering trials in March. If ready it could be available to some professional categories by autumn 2020.
  • Frontier IP Group PLC’s (LON:FIPP) portfolio company The Vaccine Group is working on formulations for animals to prevent coronaviruses from infecting humans againa.
  • German company CureVac was subject to a tug of war between the country's government and Donald Trump, who prompted outrage by attempting to buy the low-cost coronavirus vaccine developer last month.
  • Other candidates are being studied by Inovio, the Shenzhen Geno-Immune Medical Institute, CanSino Biologicals and a partnership between Soligenix and the University of Hawaii.

Diagnostics and equipment

  • Several companies are focusing on serology tests, which target antibodies to see whether the person has had the virus. According to analysts at Credit Suisse, they are “critical” in understanding immunity and potentially lift restrictions. Abbott and Eurofins announced the launch of their tests in mid-April, while Roche is developing one scheduled to be ready in early May.
  • Novacyt PLC (LON:NCYT) has been one of the pioneers in swab testing, launching the first kit in February, followed by a second one, designed to deliver faster results, in March. It is manufacturing 4mln tests per month. It is also developing a new test that does not require certain extraction reagents which are lacking throughout the market.
  • Genedrive PLC (LON:GDR) has partnered with Cytiva to have tests ready by May.

RECENT POSTS

The Transformational Impact of Artificial Intelligence on the Patient-Physician Relationship

In today’s ever-evolving healthcare landscape, the integration of artificial intelligence (AI) has ushered in a new era of possibilities, presenting…

What is Medical Communications? The definitive guide.

Medical Communications. The demand for clear and integrated dissemination of scientific knowledge is critical for the Pharmaceutical industry. Medical communications—or…

Enhancing engagement with healthcare professionals (HCPs): How AI is transforming Pharma relationships.

Pharmaceutical companies are progressively turning to the use of Artificial Intelligence (AI) as a tool to transform several aspects of…

Six communication trends Pharma needs to watch in 2024.

As we approach 2024, the Pharma industry’s focus on developing and maintaining meaningful relationships with healthcare professionals (HCPs) will only…

The EU Artificial Intelligence Act: A New Era of Regulation 
The EU's proposed AI Act, the world's first comprehensive legal framework for AI, is set to revolutionize global AI regulation. Learn about its risk classification levels and the potential implications for the Life Sciences industry.
0 +

YEARS IN

MARKET

0 +

THERAPY

AREAS

WORK IN

0 +

COUNTRIES


GET IN TOUCH

Whether you’re looking for effective solutions to transition F2F meetings to a virtual or online environment, support with clinical trials, medical advisory boards, symposia, key opinion leader (KOL) management, internal medical training, medical writing or speaker training programs and more, count on our 16-year experience and expertise over 40 therapeutic areas.

SDM also offers strategic consulting services and can help with communication and engagement of your target audiences as part of market development opportunities.

Discover why over 95% of clients are “Extremely Satisfied” with SDM and over 90% say the agency deliver “Much more than expected”.